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Effects of royal jelly on liver paraoxonase activity in rats treated
with cisplatin
Serap YILDIRIM1, Ali KARADENİZ2, Akar KARAKOÇ3, Abdulkadir YILDIRIM3, Yıldıray KALKAN4,
Nejdet ŞİMŞEK5

Aim: To evaluate the protective effects of royal jelly (RJ) on the changes caused by cisplatin in paraoxonase-1 (PON-1)
and arylesterase (ARE) activities.
Materials and methods: Twenty-four Sprague-Dawley rats were divided into 4 groups of 6: control, royal jelly (300 mg
kg−1 day−1), cisplatin (7 mg kg−1 body weight), and royal jelly (300 mg kg−1 day−1) plus a single dose of cisplatin (7 mg
kg−1 body weight). After the experimental procedures, blood and liver tissue samples were taken from each animal. The
effects of RJ and cisplatin were evaluated by PON-1, ARE (in liver homogenates), and serum alanine aminotransferase
measurements. The liver tissue was also histologically examined.
Results: Administration of cisplatin reduced the PON-1 and ARE activities in the liver. However, in the rats given a
pretreatment with RJ before the injection of cisplatin, the reduction caused by the cisplatin in the PON-1 and ARE
activities was prevented at a significant level. These biochemical observations were supported by histological findings
and suggested that RJ restored the cisplatin-induced structural alterations in the liver tissue by the way of its antioxidant,
radical scavenging, and antiapoptotic effects.
Conclusion: RJ may be a potential preventive agent against the hepatic toxicity associated with cisplatin therapy.
Key words: Arylesterase, cisplatin, oxidative stress, paraoxonase, royal jelly

Sisplatin ile tedavi edilen sıçanlarda karaciğer paraoksonaz aktivitesi üzerine arı
sütünün etkileri
Amaç: Sisplatinin neden olduğu paraoksonaz-1 (PON-1) ve arilesteraz (ARE) aktivitelerindeki değişiklikler üzerinde
arı sütünün koruyucu etkilerini değerlendirmek.
Yöntem ve gereç: Yirmi dört Sprague-Dawley sıçan, 6’şarlı 4 gruba bölündü: Kontrol; arı sütü (300 mg kg−1 gün−1);
sisplatin (7 mg kg−1 vücut ağırlığı) ve arı sütü (300 mg kg−1 gün−1) + tek doz sisplatin (7 mg kg−1 vücut ağırlığı). Tüm
hayvanlardan deneyler sonrası karaciğer dokusu ve serum örnekleri alındı. Arı sütü ve sisplatinin etkileri PON-1, ARE
(karaciğer homojenatında) ve serum alanin aminotransferaz ölçümleriyle değerlendirildi. Ayrıca karaciğer dokusu
histolojik olarak incelendi.
Bulgular: Sisplatin uygulaması, karaciğer dokusunda PON-1 ve ARE aktivitelerini azalttı. Bununla birlikte sisplatin
enjeksiyonu öncesi arı sütü uygulanan hayvanlarda, sisplatinin neden olduğu PON-1 ve ARE aktivitelerindeki
azalmanın anlamlı düzeyde önlendiği görüldü. Ayrıca bu biyokimyasal gözlemler, histolojik bulgularla da desteklendi ve
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antioksidan, radikal toplayıcı ve antiapopitotik etkileriyle arı sütünün, sisplatinin neden olduğu karaciğer dokusundaki
yapısal değişiklikleri engellediği görüldü.
Sonuç: Arı sütü, sisplatin tedavisiyle ilgili oluşan karaciğer toksisitesine karşı potansiyel koruyucu ilaç olarak
kullanılabilir.
Anahtar sözcükler: Arilesteraz, sisplatin, oksidatif stres, paraoksonaz, arı sütü

Introduction
Royal jelly (RJ), a food item secreted by worker
honeybees, is a mixture that contains protein, glucose,
lipid, vitamins, and minerals (1). RJ is widely used as
a commercial medical product. Previous studies have
shown that RJ has a number of physiological effects,
such as antiinflammatory, antitumor, antiallergic, and
antioxidant activities (2). Şimşek et al. (3) reported in
their study on rats that an oral RJ application of 300
mg kg−1 day−1 increases the number of erythrocytes
and their diameters; therefore, it could be used as a
supportive antioxidant molecule in anemic patients.
Guo et al. (2) stated that RJ peptides have a protective
effect against lipid peroxidation caused by free
radicals, both under in vivo and in vitro conditions.
Cisplatin (cis-diamine-dichloroplatinum) is one
of the major drugs used in the treatment of cancer. It
is commonly used in the treatment of such cancers as
lung, ovarian, and testicular cancer (4,5). However,
cisplatin may lead to serious adverse effects if used
in high doses. Clinical use is limited by its toxic
side effects, which occur primarily in the liver and
then in the bone marrow, kidneys, and other organs
(6,7). Cisplatin toxicity may occur with different
mechanisms. Different studies performed so far
have shown that cisplatin leads to the formation of
reactive oxygen species, lipid peroxidation, and DNA
damage (8). Therefore, one of the issues with which
one should be careful in cancer treatment is the
prevention of the oxidative stress caused by cisplatin.
The paraoxonase (PON) multigene family is
composed of 3 members: PON-1, PON-2, and PON3 (9). PON-1 is a calcium-dependent ester hydrolase
that has both PON and arylesterase (ARE) activities.
The PON-1 enzyme, synthesized mainly in the liver,
is a protein that possesses a hydrolytic effect on many
substrates, including organophosphates, aryl esters,
and lactones (10,11). Similar to PON-1, PON-3 is
expressed mostly in the liver and secreted into the
368

blood, but it is approximately 2 orders of magnitude
less abundant than PON-1. PON-2 is not detectable
in serum, although it is expressed in many tissues,
including brain, liver, kidney, and testis.
It has been reported in many studies that PON-1
has an antioxidant effect against the lipid peroxidation
caused by free radicals on cell membranes and
lipoproteins (12-14). The purpose of this study was
to examine the probable protective effects of RJ on
the oxidative organ damage caused by cisplatin. To
this end, the antioxidant effects of RJ were analyzed
with PON-1 and ARE enzyme activities measured in
liver tissues, as well as histological changes.
Materials and methods
Animals and experimental procedure
This experimental study was conducted with
the approval of the local ethics board for animal
experiments at Atatürk University. Twenty-four
female adult Sprague-Dawley rats (about 200 g) were
used. During the study, the rats were kept in metal
cages at 22-24 °C with a L/D photoperiod of 12:12,
and they were fed commercial standard rat food and
tap water. They were divided into 4 groups of 6, as
follows: the control group (Group C), the group that
was given RJ (Group RJ), the group that was given
cisplatin (Group CP), and the group that was given
RJ + cisplatin (Group RJ + CP). The rats in Group
C were fed standard rat food and tap water, while
Group RJ rats were given RJ at 300 mg kg−1 day−1
(Balen Royal Jelly, 300 mg capsule, Arı Mühendislik,
Ankara, Turkey) through an orogastric tube for 15
days. Group CP rats were given a single dose of CP [7
mg kg−1 body weight, intraperitoneally (i.p.)]. Group
RJ + CP rats were given RJ at 300 mg kg−1 day−1
through an orogastric tube for 15 days, and were
then given a single dose of cisplatin (7 mg kg−1, i.p.).
The doses of cisplatin and RJ used in this study were
selected in accordance with previous studies (15,16).
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Taking of tissue and blood samples and biochemical
measures
The animals in the control and experimental groups
were anaesthetized 24 h after the end of the study
with an injection of sodium pentobarbitone 60 mg
kg−1 of body weight, i.p. The rats were then killed by
taking blood samples from the intracardiac site, and
liver tissues were immediately removed.
Blood samples were centrifuged for 5 min at 3500
× g and their sera were separated and stored at –80 °C
until analysis. Tissue samples were cleaned using an
ice-cold solution of isotonic NaCl for the removal of
blood spots, and they were then dried with blotting
paper. Approximately 300 mg of liver tissue from each
rat was weighed and homogenized within the icecold buffer solution (50 mM Tris-HCl buffer, pH 8.0,
containing 2 mM CaCl2) (OMNI TH homogenizer,
OMNI, Warrenton, VA, USA). Tissue homogenates
were centrifuged at 15,000 × g for 15 min (4 °C) and
the supernatant was kept at –80 °C for biochemical
analysis. Tissue protein levels were determined via
the Bradford method (17), and the serum alanine
aminotransferase (ALT) level was determined with
a Roche Cobas biochemical autoanalyzer using a
commercial kit (Roche Diagnostics, Mannheim,
Germany) and was expressed as U L−1.
Measurement of PON-1 and ARE activities
PON-1 and ARE activities were assessed by methods
described previously (18,19), with some modifications.
The original method was semiautomatized with the
adaptation of a 96-well microplate; thus, analysis
of a multitude of samples was made possible in a
short time. Kinetic measurements were conducted
with the use of a spectrophotometric microplate
reader (PowerWave XS, Bio-Tek Instruments, Inc.,
Winooski, VT, USA) and its software program
(KC Junior software, Bio-Tek Inc.). The PON-1
measurement was taken at 405 nm and the ARE
measurement was taken at 270 nm. As the ARE
measurements were made at an ultraviolet wavelength
(270 nm), a 96-well UV plate was used for the assays.
For the measurements of PON-1 and ARE activities,
diethyl-p-nitrophenyl phosphate (Sigma, St. Louis,
MO, USA) and phenyl acetate (Sigma) were used as
the substrates, respectively (19). Molar absorption
coefficients were used in the calculation of the PON1 and ARE activities (17100 M−1 cm−1 and 1310 M−1

cm−1, respectively). One unit of PON-1 activity was
defined as 1 nmol 4-nitrophenol mL serum−1 min−1
and 1 unit of ARE activity was defined as 1 mmol
phenol mL serum−1 min−1. Tissue-specific activities
of PON-1 and ARE in the liver were calculated and
the results were expressed as U mg protein−1.
Histological procedure
Liver tissue samples were fixed in 10% buffered neutral
formalin and embedded in paraffin. The paraffin
blocks were cut to thicknesses of 5-7 μm and stained
with Mallory’s triple staining technique, as modified
by Crossman. Stained specimens were examined
under a Nikon i50 light microscope. Apoptotic
cells were determined immunohistochemically as
pyknotic, hyperchromatic nuclei, and caspase-3positive reactions. For the immunohistochemistry
examination, primary antibody monoclonal
caspase-3 (dilution: 1/25, BioVision-3015-100,
BioVision, Milpitas, CA, USA) and biotinylated
secondary antibody (Universal LSAB Kit-K0690,
Dako, Glostrup, Denmark) were used. The antibody
binding sites were visualized with diaminobenzidine
(Sigma) and evaluated by high-power light
microscopic examination (Nikon i50). All of the
apoptotic staining cells were estimated with an image
processing system (Kameram SLR, 1.6.1.0, Mikro
Sistem Ltd. Şti., İstanbul, Turkey) in 4 different
areas of 0.2 mm2 at 20× objective. Damaged cells
were not evaluated. The marked cells were counted
automatically with the same image analysis program.
Statistical analysis
The results were expressed as means ± standard
deviation (SD). Differences among the groups were
assessed with one-way ANOVA following Tukey’s
post hoc multiple comparison test. P ≤ 0.05 was
statistically significant. SPSS 15.0 for Windows (SPSS
Inc., Chicago, IL, USA) was used for these analyses.
Results
Effects of cisplatin and RJ on serum ALT levels
When compared with Group C, cisplatin led to a
significant increase in the serum ALT levels. While
ALT activity was 32.8 ± 4.5 U L−1 in Group C, it
was 50.4 ± 5.7 U L−1 in Group CP (P < 0.001). This
increase in ALT activity was partially prevented by
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pretreatment with RJ. ALT activity was 47.9 ± 4.7 U
L−1 in Group RJ + CP, but this decrease in ALT activity
did not show statistically significant differences
compared with Group CP (P > 0.05). These results
are shown in Figure 1.
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Figure 1. Serum ALT activities in all of the groups. *P < 0.001 vs.
Group C and Group RJ. C, control (Group C); RJ, royal
jelly (Group RJ); CP, cisplatin (Group CP).
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it was 5.2 ± 1.1 U mg protein−1 in Group CP (P <
0.005). Similarly, ARE activity was lower in Group
CP (4.1 ± 0.7 U mg protein−1) when compared with
Group C (6.5 ± 0.4 U mg protein−1) (P < 0.001). Data
concerning the PON-1 and ARE activities measured
in the study groups are presented in Figures 2 and 3.
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Cisplatin reduces the activities of liver PON-1 and
ARE
PON-1 and ARE activities were measured in liver
homogenates. When compared with Group C, a dose
of cisplatin administration (Group CP) was observed
to significantly decrease the PON-1 enzyme activities
in the liver tissue (Figure 2). While liver PON-1
activity was 8.1 ± 1.6 U mg protein−1 in Group C,

PON-1 activity (U mg protein–1)

12
10

CP

RJ+CP

Figure 3. Liver tissue ARE activities in all of the groups. *P <
0.001 vs. both Group C and Group RJ and **P < 0.05
vs. Group C.

Protective effect of RJ on the hepatotoxicity
While cisplatin decreased the antioxidant PON
enzyme activities in the liver, 300 mg kg−1 RJ (in
Group RJ + CP) administered orally for 15 days
was observed to significantly prevent the decrease
in PON-1 and ARE activities caused by cisplatin.
However, when compared with the other groups, the
highest PON-1 and ARE activities were measured
only in Group RJ. Data concerning these results are
shown in Figures 2 and 3.
Histological results
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Figure 2. Liver tissue PON-1 activities in all groups. *P < 0.005
vs. Group C and **P < 0.001 vs. Group RJ.
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For histological evaluation, although the livers of
Group C and Group RJ showed normal histological
structure (Figures 4A and 4B), histological alterations
were observed only in Group RJ + CP and Group
CP. Microscopic changes were characterized by
sinusoidal dilatation, mononuclear cell infiltrations,
congestion and hepatocellular degeneration, and
apoptosis (Figures 4C-4E). In Group RJ + CP,
interesting decreases in the cytoplasmic alteration
of the hepatocytes or sinusoidal dilatations around
the central vein were found in comparison to
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Figure 4. A) Group C, B) Group RJ, C-E) Group CP, and F) Group RJ + CP: mononuclear cell infiltrations are obvious
in portal areas (open arrow), sinusoidal congestion and dilatations (arrows), and apoptotic cells (arrow
heads). Light micrograph of a transverse section of the liver stained with triple stain modified by Crossman,
625×, CV = central vein.
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Group CP (Figure 4F). Furthermore, in this study,
apoptotic immunopositive reactions in the liver
were investigated with caspase-3 antibody. Apoptotic
activity comparisons of the groups are shown in
Figure 5. Caspase-3-immunoreactive cells were
intensely observed around the central vein of the liver
in Group CP (Figure 5A) and throughout the lobules
(Figure 5B). We saw that the number of apoptotic
cells were increased in the liver tissue of Group CP
when compared with Group RJ + CP, which showed

significantly decreased apoptotic cell numbers (P <
0.05, Figures 5C and 5D).
Discussion
Cisplatin is one of the most effective chemotherapeutic
agents in cancer treatment. It is used in the treatment
of malign cancers of several tissues and organs, such
as lung, testis, ovary, bladder, and head-neck (7).
However, the side effects of cisplatin restrict its use

A

B

Mean of apoptotic cell

15

10

5

0
Control

RJ

CP
Groups

RJ+CP

C

D
Figure 5. Apoptotic cell numbers (n 0.2 mm–2) in all of the groups and caspase-3-positive cells in Group CP (A and B) and Group RJ
+ CP (C and D) by streptavidin biotin peroxidase stain (275×). The numbers of apoptotic cells in the unit area in Group C
and Group RJ were statistically significant compared with those of Group CP and Group RJ + CP (P < 0.05). The numbers of
apoptotic cells in Group RJ + CP were significantly decreased compared with Group CP (P < 0.005).

372

S. YILDIRIM, A. KARADENİZ, A. KARAKOÇ, A. YILDIRIM, Y. KALKAN, N. ŞİMŞEK

and effectiveness. Hepatotoxicity, nephrotoxicity,
neurotoxicity, hair loss, nausea, and vomiting are
common side effects (6,7,20). Its toxic effects on
various organs, including the liver, make it necessary
to carefully regulate the dosage of cisplatin (6).
Recent studies have largely focused on the ways
to protect against cisplatin hepatotoxicity (21,22). To
the best of our knowledge, this study is the first to
research the protective effect of RJ against cisplatin
hepatotoxicity. It has already been stated in the
literature that some antioxidant molecules that are
influential as scavengers or prevent the formation of
reactive oxygen species eliminate the hepatotoxicity
caused by cisplatin (21). Therefore, in this study, focus
was placed on the probable protective effects of RJ on
the oxidative hepatic damage caused by cisplatin.
An injection of cisplatin, if at a high dosage
(>30 mg kg–1), may lead to death. In this study,
intraperitoneal injections of cisplatin in rats led
to a significant increase in the serum ALT activity.
Hepatotoxicity caused by cisplatin was evaluated
with PON-1 and ARE activities measured in the liver
tissue and serum ALT activity. As the liver plays a key
role in the synthesis of serum paraoxonase, it was
reported in previous studies that the measurement of
PON-1 activity could be used as a liver function test
(23,24). In this study, the existence of hepatotoxicity
in the rats to which cisplatin was administered was
proven by the increased serum ALT and decreased
hepatic tissue PON-1 and ARE activities. Increased
serum ALT activity in the cisplatin hepatotoxicity in
the experimental animals was also reported by Liao
et al. (6) and Kart et al. (21).
Many studies have been conducted so far on
the role of the PON-1 enzyme in the pathogenesis
of various diseases (25), and most have focused on
cardiovascular diseases (26,27). Although serum
PON-1 enzyme is primarily synthesized in the liver
(23), there are a limited number of studies on the
PON-1 activity of the liver.
PON-1 is an enzyme that has an antioxidant
quality, and thus it has been reported that PON1 serum and/or tissue activity changes in cases of
oxidative stress (12,26). In their comparative study on
human and rat liver tissue, Trudel et al. (28) reported
that PON-1 expression decreases in the case of acute
oxidative stress caused by the iron-ascorbate oxygen-

generating system. This case shows that PON-1
responds to acute damage (23). Moreover, Ferré et al.
(24) stated that PON-1 activity in chronic liver illness
is associated with the degree of hepatic dysfunction.
Similar to the results of Trudel et al. (28), we observed
that 24 h after the administration of cisplatin, namely
in the acute period, PON activities decreased in the
hepatic tissue samples. Considering these results, we
are of the opinion that measurement of PON-1 and
ARE activities may be used as a helping biomarker of
acute hepatotoxicity.
As there is not a study that assesses the relationship
between cisplatin hepatotoxicity and PON-1/ARE
activities, it was difficult to compare our results to
others. Therefore, we found it best to have a look at
other studies that examine the oxidant/antioxidant
status in cisplatin hepatotoxicity. Even though the
underlying mechanisms of the hepatotoxicity caused
by cisplatin have not been understood exactly, it has
been reported that it might be related to oxidative
stress (6,29).
A decrease was reported in the oxidative stress
(30) and enzymatic (31) and nonenzymatic (32)
antioxidant defense system that was caused by the
increase in the reactive oxygen species, and major
changes were observed in cisplatin toxicity. In the
present study, the activity of PON (both PON-1 and
ARE), which is an antioxidant enzyme, decreased
significantly in cisplatin-injected rats. This result
seems to confirm the literature information regarding
the effect of a decreased enzymatic antioxidant
defense system in cisplatin hepatotoxicity. However,
we have not been able to decide exactly whether the
decreased PON-1 and ARE activities observed in
cisplatin hepatotoxicity are a cause or a result.
In this study, the in vivo protective effects of
RJ against cisplatin hepatotoxicity were examined.
As seen in Figure 2, both tissue and serum PON1 and ARE activities decreased significantly after
the intraperitoneal cisplatin injection. However, a
15-day-long administration of RJ was observed to
significantly prevent the decrease in liver paraoxonase
enzyme activities caused by cisplatin (Figure 2). This
effect is probably related to the antioxidant quality
of RJ. As stated above, increased oxidative stress
and/or a decreased enzymatic antioxidant defense
system plays an important role in cisplatin toxicity
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(6,29). Furthermore, recent research shows that RJ
peptides have a strong hydroxyl radical scavenging
quality. Accordingly, RJ peptides show antioxidant
activity, preventing lipid peroxidation (2). Therefore,
it is probable that RJ cures PON-1 and ARE activities
through antioxidative effect mechanisms. That is, RJ
probably inactivates the hydroxyl radicals, which are
indeed very reactive (2), thus protecting the PON-1 and
ARE enzymes from the harmful effects of free radicals.
The above biochemical results correlated well
with the histological results from the liver tissue,
which revealed sinusoidal dilatation, mononuclear
cell infiltration, congestion and hepatocellular
degeneration, and apoptosis. The histological
pictures and evaluations of apoptosis are presented
in Figures 4 and 5. The livers of Group C and Group
RJ showed normal histological views (Figures 4A
and 4B). However, rats given cisplatin alone, had
hepatocellular degeneration and inflammatory
infiltrations in the liver sections (Figures 4C and 4E).
The liver is known to accumulate significant amounts
of cisplatin, and thus hepatotoxicity can be associated
with cisplatin treatment (6). Cisplatin is thought to
kill cells primarily by forming DNA adducts, causing

G2 arrest in the cell cycle and triggering apoptosis
(33). Apoptosis is a common feature of hepatotoxicity
induced by many chemicals; it may precede necrosis,
as in the hepatotoxicity induced by cisplatin (34).
On the other hand, the liver cells in Group RJ + CP
rats were nearly normal in histological architecture.
Similar findings were also reported by Kart et al. (21)
and Yüce et al. (35), demonstrating the structural
changes in the liver tissue of cisplatin-treated animals
and its reverse action by different agents such as
caffeic acid, phenethyl ester, or ellagic acid.
As a result, cisplatin decreases the liver PON1 and ARE activities in rats. A combination of RJ
and cisplatin prevents this decrease significantly.
This result shows that RJ has a potential effect on
paraoxonase enzyme activity; therefore, RJ can
be used as a protective natural product against the
hepatotoxicity caused by cisplatin.
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